Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BVS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 110.38% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 465.83M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 3 | Beta 0.85 | 52 Weeks Range 5.73 - 14.38 | Updated Date 07/4/2025 |
52 Weeks Range 5.73 - 14.38 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.51% | Operating Margin (TTM) 4.01% |
Management Effectiveness
Return on Assets (TTM) 3.33% | Return on Equity (TTM) -20.24% |
Valuation
Trailing PE - | Forward PE 10.64 | Enterprise Value 809155422 | Price to Sales(TTM) 0.82 |
Enterprise Value 809155422 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.43 | Enterprise Value to EBITDA 21 | Shares Outstanding 66357600 | Shares Floating 34340727 |
Shares Outstanding 66357600 | Shares Floating 34340727 | ||
Percent Insiders 11.87 | Percent Institutions 71.55 |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew's biologics division. It focuses on developing and commercializing orthobiologic solutions. Over time, it has expanded its product portfolio through internal development and acquisitions.
Core Business Areas
- Active Healing Therapies: Focuses on bone graft substitutes and related products used in fracture repair and spinal fusion procedures.
- Pain Relief Therapies: Focuses on products that provide pain relief through injection treatments such as viscosupplementation for osteoarthritis.
- Surgical and Wound Care: Focuses on wound care products used in post surgical recovery.
Leadership and Structure
The leadership team includes CEO Tony Bihl, CFO Ben Burky, and other key executives. The company has a functional organizational structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- DUROLANE: DUROLANE is a single-injection hyaluronic acid product for osteoarthritis pain relief. Competitors include Sanofi (SYNTHOVISC), Seikagaku Corporation (GEL-ONE), and other hyaluronic acid products. Global market share varies, with Durolane holding a significant share of the single injection market. Specific revenue data fluctuates yearly and is available in Bioventus' financial reports.
- OSTEOAMP: OSTEOAMP is a bone graft substitute used in orthopedic procedures. Competitors include Medtronic (INFUSE), NuVasive (ATTRAX), and Stryker (OP-1). OSTEOAMP market share data is available in Bioventus' financial reports. Revenue data fluctuates yearly and is available in Bioventus' financial reports.
- EXOGEN: EXOGEN is a non-invasive bone healing system that uses ultrasound. Competitors include Orthofix (Physio-Stim), Zimmer Biomet (SpinalStim), and other bone growth stimulators. Market share and revenue fluctuate yearly and are available in the Bioventus' financial reports.
Market Dynamics
Industry Overview
The orthobiologics market is growing due to an aging population, increasing incidence of osteoarthritis and sports injuries, and advancements in regenerative medicine.
Positioning
Bioventus Inc. is a key player in the orthobiologics market, with a focus on active healing and pain relief therapies. Its competitive advantages include a diversified product portfolio and a strong distribution network.
Total Addressable Market (TAM)
The global orthobiologics market is estimated to be in the billions of dollars. Bioventus is positioned to capture a portion of this TAM through its product offerings and market penetration strategies.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Diversified product portfolio
- Strong distribution network
- Focus on innovation
Weaknesses
- Dependence on key products
- Exposure to regulatory risks
- Intense competition
- Small to mid-sized company
Opportunities
- Expanding into new geographic markets
- Developing new products and therapies
- Acquiring complementary businesses
- Increasing adoption of orthobiologics
Threats
- Increased competition from larger players
- Pricing pressures
- Changes in reimbursement policies
- Product liability claims
Competitors and Market Share
Key Competitors
- JNJ
- ZBH
- MTD
Competitive Landscape
Bioventus competes with larger companies like Johnson & Johnson, Zimmer Biomet, and Medtronic. Its advantages include a focused product portfolio and a strong distribution network, while disadvantages include smaller size and resources.
Major Acquisitions
Bioness
- Year: 2018
- Acquisition Price (USD millions): 45
- Strategic Rationale: Expanded Bioventus' product portfolio into neurorehabilitation and pain management.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product sales, acquisitions, and market expansion.
Future Projections: Analyst estimates for future growth are available from financial news providers. Projections depend on the general market, company financials, and market conditions.
Recent Initiatives: Recent initiatives include new product launches, acquisitions, and partnerships.
Summary
Bioventus is a mid-sized orthobiologics company with a focused product portfolio and established market presence. Its strengths lie in its innovative products and distribution network, but faces competition from larger players and regulatory risks. Growth opportunities exist through market expansion and new product development. Continuous innovation and successful integration of acquisitions are vital for Bioventus' long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bioventus Inc. SEC Filings
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 930 | Website https://www.bioventus.com |
Full time employees 930 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.